Similar articles

Abstract: Until now, there has been a lack of standard and effective treatments for patients with recurrent malignant tumors or abdominal and pelvic malignancies with extensive invasion (Morris, 2000). Generally, these patients face problems such as inability to undergo surgery or chemotherapy resistance (Combs et al., 2016). Re-radiotherapy has achieved a prominent place in the treatment of patients who have received radiotherapy previously and developed in-field recurrences (Straube et al., 2018). However, re-radiotherapy is very complicated, requiring comprehensive consideration of appropriate radiation dose, interval from first radiotherapy, boundary of the radiotherapy target area, and damage to surrounding normal tissues (Straube et al., 2019). In other words, it is necessary to focus on the protection of surrounding normal tissues while maximizing the efficacy of re-radiotherapy in such patients.

低剂量率脉冲放疗模式显著提高腹部盆腔恶性肿瘤的治疗效果

[1]BlackfordAN, JacksonSP, 2017. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell, 66(6):801-817.

[2]CombsSE, SchmidTE, VaupelP, et al., 2016. Stress response leading to resistance in glioblastoma—the need for innovative radiotherapy (iRT) concepts. Cancers, 8(1):15.

[3]DaiXF, TaoD, WuHG, et al., 2009. Low dose hyper-radiosensitivity in human lung cancer cell line A549 and its possible mechanisms. J Huazhong Univ Sci Technol Med Sci, 29(1):101-106.

[4]ElkindMM, Sutton-GilbertH, MosesWB, et al., 1965. Radiation response of mammalian cells grown in culture. V. Temperature dependence of the repair of X-ray damage in surviving cells (aerobic and hypoxic). Radiat Res, 25:359-376.

[5]HarneyJ, ShahN, ShortS, et al., 2004. The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiother Oncol, 70(3):319-329.

[6]LiJ, ZhaoZH, DuGB, et al., 2019. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: study protocol for a prospective multi-center phase II trial. Medicine, 98(26):e16176.

[7]LiY, YuanJ, 2021. Role of deubiquitinating enzymes in DNA double-strand break repair. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(1):63-72.

[8]MartinLM, MarplesB, LynchTH, et al., 2013. Exposure to low dose ionising radiation: molecular and clinical consequences. Cancer Lett, 338(2):209-218.

[9]MorrisDE, 2000. Clinical experience with retreatment for palliation. Semin Radiat Oncol, 10(3):210-221.

[10]OlivePL, 2004. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol, 75:355-373.

[11]PavlopoulouA, BagosPG, KoutsandreaV, et al., 2017. Molecular determinants of radiosensitivity in normal and tumor tissue: a bioinformatic approach. Cancer Lett, 403:37-47.

[12]StraubeC, ScherbH, GemptJ, et al., 2018. Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma—the GlioCave study (NOA 17-ARO 2016/3-DKTK ROG trial). BMC Cancer, 18:15.

[13]StraubeC, KesselKA, ZimmerC, et al., 2019. A second course of radiotherapy in patients with recurrent malignant gliomas: clinical data on re-irradiation, prognostic factors, and usefulness of digital biomarkers. Curr Treat Options Oncol, 20(10):71.

[14]TodorovicV, PrevcA, ZakeljMN, et al., 2020. Pulsed low dose-rate irradiation response in isogenic HNSCC cell lines with different radiosensitivity. Radiol Oncol, 54(2):168-179.

[15]TomeWA, HowardSP, 2007. On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br J Radiol, 80(949):32-37.

[16]WangQ, XiaoZY, LinZY, et al., 2017. Autophagy influences the low-dose hyper-radiosensitivity of human lung adenocarcinoma cells by regulating MLH1. Int J Radiat Biol, 93(6):600-606.

[17]YaoH, QiuH, ShaoZY, et al., 2016. Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine, 12(8):2261-2271.

[18]ZhangF, GongZ, 2021. Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(1):38-46.